# Intratumoral Cisplatin for Resectable NSCLC

> **NCT04809103** · PHASE1 · COMPLETED · sponsor: **University of Vermont** · enrollment: 6 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** cis-diamminedichloroplatinum

## Key facts

- **NCT ID:** NCT04809103
- **Lead sponsor:** University of Vermont
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-08
- **Primary completion:** 2025-10-01
- **Final completion:** 2025-10-01
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04809103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04809103, "Intratumoral Cisplatin for Resectable NSCLC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04809103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*